FHTX Foghorn Therapeutics
- 5.490
- +0.260+4.97%
- 5.490
- 0.0000.00%
Foghorn Therapeutics News
Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances
Foghorn Therapeutics Analyst Ratings
HC Wainwright & Co. : The Foghorn Therapeutics (FHTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Foghorn Therapeutics Analyst Ratings
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Lowers Price Target to $6
Foghorn Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX), Aurinia Pharmaceuticals (AUPH) and Biogen (BIIB)
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Foghorn Therapeutics Analyst Ratings
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $10 From $13, Maintains Equal-Weight Rating
Morgan Stanley Sticks to Its Hold Rating for Foghorn Therapeutics (FHTX)
Bank of America Securities Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
Goldman Sachs Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $19
Analyst Ratings for Foghorn Therapeutics
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating
Foghorn Therapeutics (FHTX) Gets a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Analysis
Price Target
No Data
